Willing to Win - Biotech Leaders Against All Odds Episode 7
Every scientist who enters drug development believes the science will find its way. That if the biology is right, the path forward is clear. That conviction is enough. Zoltan Magyarics believed it too. Then the phase two failed. The lead program died. And the belief that great science finds its own way broke with it.
In this episode of Willing To Win, Christian Rados sits down with Zoltan Magyarics, physician, PhD immunologist, and VP of R&D at AOP Health. Over 15 years and four companies Arsanis, Bloom Diagnostics, Leyden Labs, and AOP Health - Zoltan has been inside the room when the money runs out, when the program collapses, and when the romantic idea of what science is worth collides with the financial reality of what you can actually afford to do.
This is the confession the industry has in private but never on record.
The study design wasn't chosen because it was right. It was chosen because it was the only one they could afford. The decision that looked like strategy was a decision that made itself. And in European biotech culture, when it goes wrong, you don't get called experienced. You get called a fallen angel. Zoltan has watched brilliant founders fail not because they were wrong about the science - but because they never understood who would pay for the drug, never built real optionality, and never admitted out loud what was actually driving their decisions.
In this episode, Zoltan breaks down:
Why most biotechs are functionally one-trick ponies - even with a full portfolio
The finance-driven study design decision nobody openly admits is happening
What early-stage founders systematically misunderstand about payers and commercial endpoints
Why the decision that feels like strategy is often a decision that made itself
What failure across Arsanis, Bloom Diagnostics, Leyden Labs, and AOP Health actually taught him about surviving the game
Why European biotech culture punishes failure - and why that has to change
The one piece of advice every early-stage founder needs to hear before they design their next study
This is not a success story. It is a forensic look at how idealism dies inside the biotech machine - and what the people who survive it had to unlearn to keep going.
🎧 Listen and FollowAccess the full episode on all platforms:👉 https://linktr.ee/willingtowinpodcast
🔔 Subscribe to Willing To WinConversations with biotech founders, CMOs, and drug developers who have operated across every side of the table. No highlight reels. No pitch deck versions.👉 / @willingtowinpodcast
New episodes every week featuring leaders from biotech, pharma, and high-stakes decision-making.
Connect with Zoltan Magyaricshttps://www.linkedin.com/in/zoltan-magyarics-ba2163174/
Connect with Christian Radoshttps://www.linkedin.com/in/christianrados-biotechdreamteams/ www.rados-recruiting.com
If you have ever watched a great program fail for reasons that had nothing to do with the science - or suspected that the model itself might be broken — this episode is the conversation you have been waiting for someone to have out loud.
#biotech #pharma #drugdevelopment #leadership #startup #entrepreneurship #venturecapital #CEO #founder #clinicaldevelopment #AOPHealth #LeydenLabs #BloomDiagnostics #Arsanis #willingtowin #lifesciences #biopharma #raredisease #healthtech #innovation
Portugal